ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

08 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

11 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

05 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

22 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

14 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

07 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

07 Dec 2024 18:30:22 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

03 Dec 2024 07:30:25 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

07 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07 Nov 2024 07:30:55 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

09 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

29 Aug 2024 07:30:15 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

22 Aug 2024 16:03:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

01 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

11 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

31 May 2024 07:30:26 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

29 May 2024 16:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

07 May 2024 16:05:46 By Nasdaq GlobeNewswire